BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Cancer Epigenetics Society - ECPv5.3.2.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cancer Epigenetics Society
X-ORIGINAL-URL:https://ces.b2sg.org
X-WR-CALDESC:Events for Cancer Epigenetics Society
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20180325T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20181028T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20180210
DTEND;VALUE=DATE:20180215
DTSTAMP:20260729T113554
CREATED:20170507T112805Z
LAST-MODIFIED:20171001T150958Z
UID:17852-1518220800-1518652799@ces.b2sg.org
SUMMARY:Cancer Epigenetics: New Mechanisms\, New Therapies (B4) in Breckenridge\, CO\, USA
DESCRIPTION:Bringing together both the scientific and the pharmaceutical communities\, this Keystone Symposia meeting will will focus on:  \n1) The newest findings on the mechanisms by which epigenetic pathways are established and maintained in normal and stem cells\, and how these go awry during aging and cancer\, with a special emphasis on histone modifications\, chromatin remodeling and the unexpected increased number of DNA modifications ((hydroxy)methylcytosine and methyladenine);  \n2) The growing roles of noncoding RNAs in cancer and the emergence of the new and exciting realm of RNA epigenetics;  \n3) Use of new omics technologies to interrogate altered epigenetic landscapes in tumors and assess their clinical implications;  \n4) Novel and promising therapeutic drugs aimed at reversing specific epigenetic alterations. Ultimately\, the meeting will provide great opportunities for senior and junior scientists to meet the leaders in the field from both academia and industry\, hence forging exciting interdisciplinary interactions and creating potential new collaborations in the booming area of cancer epigenetics. \nInvited Speakers:  \nKaren Adelman\, Harvard Medical School\, USA \nGeneviève Almouzni\, Centre National de la Recherche Scientifique\, France \nStephen B. Baylin\, Johns Hopkins University School of Medicine\, USA \nAznar Benitah\, ICREA and Institute for Research in Biomedicine\, Spain \nShelley L. Berger\, University of Pennsylvania\, USA \nJames E. Bradner\, Novartis Institutes for BioMedical Research\, USA \nAnne Brunet\, Stanford University\, USA \nHoward Y. Chang\, Stanford University\, USA \nMark A. Dawson\, Peter MacCallum Cancer Centre\, Australia \nLuciano Di Croce\, Centre for Genomic Regulation\, Spain \nMichaela Frye\, University of Cambridge\, UK \nFrançois Fuks\, Université Libre De Bruxelles\, Belgium \nChuan He\, University of Chicago\, USA \nPeter A. Jones\, Van Andel Research Institute\, USA \nCigall Kadoch\, Dana-Farber Cancer Institute\, Harvard Medical School\, USA \nTony Kauzarides\, University of Cambridge\, UK \nElectron Kebebew\, National Cancer Institute\, USA \nRobert E. Kingston\, Massachusetts General Hospital\, USA \nRobert MacLeod\, Ionis Pharmaceuticals\, Inc.\, USA \nChris Marine\, VIB\, Belgium \nRobert A. Martienssen\, Cold Spring Harbor Laboratory\, USA \nRonan C. O’Hagan\, Merck Research Laboratories\, USA \nKornelia Polyak\, Dana-Farber Cancer Institute\, Harvard Medical School\, USA \nRab K. Prinjha\, GlaxoSmithKline\, UK \nGideon Rechavi\, Tel Aviv University\, Israel \nDanny F. Reinberg\, HHMI/New York University\, USA \nAli Shilatifard\, Northwestern University\, USA \n  \nDeadlines: \nScholarship Deadline: Oct 10\, 2017 \n Discounted Abstract Deadline: Oct 10\, 2017 \n Abstract Deadline: Nov 8\, 2017 \n Discounted Registration Deadline: Dec 12\, 2017  \nScientific Organizers: François Fuks and Anne Brunet\n 
URL:https://ces.b2sg.org/event/keystone-feb2018/
LOCATION:Beaver Run Resort\, 620 Village Rd\, Breckenridge\, CO\, 80424\, United States
CATEGORIES:Meetings
ATTACH;FMTTYPE=image/jpeg:https://ces.b2sg.org/wp-content/uploads/2017/05/keystone-e1494159273833.jpg
END:VEVENT
END:VCALENDAR